In the first quarter of FY2027, Ideal Scientific Industries achieved net sales of \u00a520,598 million (up 12.7% YoY) and net income of \u00a513,710 million (54.3% increase). Growth was driven by overseas business and contributions from special gains, including gains from the sale of investment securities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6413","jir_company_name":"Ideal Scientific Industries Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/6413-20260731-01.pdf","jir_short_summary":"In the first quarter of FY2027, Ideal Scientific Industries achieved net sales of \u00a520,598 million (up 12.7% YoY) and net income of \u00a513,710 million (54.3% increase). Growth was driven by overseas business and contributions from special gains, including gains from the sale of investment securities.","jir_summary":"### Financial Performance Overview\nIn the first quarter of FY2027, Ideal Scientific Industries posted net sales of \u00a520,598 million (up 12.7% YoY), operating income of \u00a51,588 million (up 7.6%), and net income of \u00a513,710 million (up 54.3%). The increase was supported by favorable currency effects from yen depreciation on overseas operations and the acquisition of shares in the Philippine sales subsidiary. Additionally, a \u00a5520 million gain from the sale of investment securities contributed to higher profits. The segments related to printing equipment showed strong performance domestically and internationally, with increases in both sales and profits.\n\n### Outlook and Shareholder Returns\nThe company maintains its full-year earnings forecast for FY2027 unchanged and will continue to respond swiftly to changes in market conditions. Procurement of raw materials and parts remains stable, and the Company plans to manage profitability despite expected effects of currency fluctuations and rising costs. Share buybacks will be implemented to enhance shareholder returns, with the number of shares outstanding unchanged and treasury stock increasing to \u00a510,015 million. Going forward, the Company will focus on expanding overseas operations and new businesses to strengthen its earnings base.","jir_financial_highlights":"Net Sales: \u00a520,598 million (Up 12.7% YoY)\nNet Income Attributable to Owners of Parent: \u00a513,710 million (Up 54.3% YoY)\nOperating Income: \u00a51,588 million (Up 7.6% YoY)","jir_category":"","jir_hashtags":"#IdealScientificIndustries, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Net sales: \u00a520,598 million (+12.7% YoY)\nNet income attributable to owners of parent: \u00a513,710 million (+54.3% increase)\nTreasury stock: \u00a510,015 million (increase)","jir_meta_title":"\u3010Ideal Scientific Industries\u3011Q1 FY2027 Financial Results | Revenue: \u00a52.06 billion (+12.7%)","jir_meta_description":"In Q1 FY2027, Ideal Scientific Industries achieved net sales of \u00a520,598 million (up 12.7% YoY) and net income of \u00a513,710 million (54.3% increase). Supported by overseas expansion and special gains.","jir_og_title":"\u3010Ideal Scientific Industries\u3011Q1 FY2027 Financial Results | Revenue: \u00a52.06 billion (+12.7%)","jir_og_description":"Ideal Scientific Industries' Q1 FY2027 financial results show net sales of \u00a52.06 billion and net income of \u00a51.37 billion, driven by overseas expansion and special gains.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16706,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-92075","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n